Jazz Pharmaceuticals' Two Ziihera-Containing Regimens Receives FDA Approval To Treat Adults With Unresectable Locally Advanced Or Metastatic Her2-Positive Gastroesophageal Adenocarcinoma

Jazz Pharmaceuticals Prices Upsized $1.1B Offering Of 1.875% Exchangeable Senior Notes Due 2032, Announces $225.0M Concurrent Share Repurchase At $249.29 Per Share

Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $287 to $300.

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.

BeOne Medicines And Max Foundation Renew Partnership To Expand Access To BRUKINSA For The Treatment Of Chronic Lymphocytic Leukemia Through 2028

Partnership serves low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively.Building on a collaboration launched in 2023, the renewed partnership reflects the